Every time I scroll through peptide groups, tirzepatide is somewhere in the mix. Half the posts get it right and half sound like a game of telephone. So here’s the plain version, for everyone in Orion Peptides. What is it? It’s a once-weekly injectable from Eli Lilly that activates two receptors, GIP and GLP-1. Semaglutide only does the GLP-1 part. That’s why people call tirzepatide a “dual agonist.” Fun detail if you like chemistry: it’s a 39-amino-acid peptide with a fatty acid chain attached. That chain helps it bind to albumin in the blood, so it sticks around for about five days. Hence the weekly schedule. Is it approved? Yes, and that matters. The FDA approved it as Mounjaro for type 2 diabetes in 2022, then as Zepbound for weight management in 2023. Same molecule, two labels. What did the trials show? In SURMOUNT-1, adults with obesity (no diabetes) on the highest dose lost about 21% of their body weight on average over 72 weeks. Placebo was around 3%. In SURMOUNT-5, a head-to-head trial, tirzepatide beat semaglutide, roughly 20% versus 14%. “Average” is doing a lot of work there. Some people lost way more, some way less. Stuff people get wrong “It’s just semaglutide with extras.” Nope. GIP is its own pathway, and that’s the point of the design. “Once the weight’s gone, it’s gone.” Not really. In SURMOUNT-4, people switched to placebo after 36 weeks regained about 14% on average, while those who kept going lost another 5% or so. “The side effects are nothing.” Mostly digestive: nausea, diarrhea, constipation, vomiting, especially when the dose goes up. But the label also carries a boxed warning about thyroid C-cell tumors (seen in rodents) and flags gallbladder problems and pancreatitis. It’s not for anyone with a personal or family history of medullary thyroid cancer or MEN 2. Why it matters for research folks It’s the benchmark now. When a new compound shows up, the first question worth asking is how it compares to tirzepatide at the same stage. Big trials, a full regulatory review, a real label. It keeps you from getting swept up by the next shiny headline.

BPC-157 is one of those peptides that seems to come up constantly in research communities. It has attracted attention because researchers have investigated it across several areas, including tissue repair, gastrointestinal models, vascular processes, and cellular signaling. At the same time, there is a lot of confusion online about what BPC-157 actually is, what the research shows, and where claims go beyond the available evidence. So what makes BPC-157 interesting from a research perspective? What Is BPC-157? BPC-157 is a synthetic peptide that has primarily been investigated in preclinical research. Much of the interest surrounding it comes from animal and laboratory studies examining processes associated with tissue repair and cellular responses. It's important to distinguish this research from established clinical evidence. Findings from preclinical models don't automatically demonstrate that the same effects will occur in humans. That's one of the most important points to keep in mind when reading online discussions about BPC-157. Why Has It Attracted So Much Research Interest? One reason is the range of biological processes that have been investigated. Research has explored BPC-157 in areas such as: - Tissue repair - Gastrointestinal injury models - Vascular responses - Angiogenesis - Inflammation-related processes - Cellular signaling - Tendon and ligament injury models This broad range is part of what makes the peptide interesting to researchers. However, "studied in multiple areas" shouldn't be interpreted as "proven effective for multiple conditions." The strength and relevance of evidence can vary significantly between research models. BPC-157 and Tissue Repair Some of the most frequently discussed BPC-157 research involves tissue repair. Preclinical studies have investigated its effects in different injury models, including models involving muscle, tendon, ligament, and other tissues. Researchers have proposed several possible mechanisms for these observations, including effects involving blood vessels, cellular signaling, and inflammatory pathways.

Can I not buy peptides on here?

Peptide Sciences was once a well-known name among researchers looking for research peptides online. Its broad catalog, product information, and testing documentation made it a familiar supplier within the research community. Following the company's closure, many researchers have been looking for alternative suppliers. As the research peptide market continues to change in 2026, several vendors have gained attention for their product selection, testing documentation, and availability. Below are some suppliers researchers may want to consider when exploring alternatives to Peptide Sciences. What Happened to Peptide Sciences? Peptide Sciences established a strong presence in the research peptide market by offering a wide selection of research compounds and providing product information and testing documentation. After the company stopped operating, researchers who previously relied on the supplier began looking for other options. The situation has also made testing transparency and product documentation increasingly important when comparing research peptide suppliers. Research Peptide Suppliers to Consider in 2026 Kylo Peptides Kylo Peptides is one supplier that researchers may come across when searching for an alternative to Peptide Sciences. The company offers research peptides and provides product-specific testing information and Certificates of Analysis for its products. Key features include: - Product-specific COAs - Independent laboratory testing - Research-use labeling - A growing selection of research peptides Researchers considering Kylo Peptides can review the available testing documentation for the specific product and lot they are evaluating. Ascension Peptides Ascension Peptides is another supplier that has attracted attention within the research peptide community. The company offers a selection of research compounds and provides another option for researchers who are looking beyond established suppliers. Factors researchers may consider include:

I came across a discussion recently that made me stop for a second. Someone had built up a stockpile of lyophilized peptides over the years and suddenly realized that they may not have been storing them the way they should have. Some were potentially 12 months old or older, and the big question was: If a peptide has been sitting around for a year without being frozen, does that mean it's ruined? The answer is a lot more complicated than “yes, throw it away” or “no, peptides are fine at room temperature.” And this is one of those areas where peptide-storage advice online gets repeated so often that it can become difficult to separate actual stability science from rules of thumb. The important point is this: A lyophilized peptide that was never frozen is not automatically a bad peptide. But you also cannot assume that an old vial is still within specification simply because the powder looks normal. Temperature is only one part of the equation. First: Does Every Lyophilized Peptide Have to Be Frozen? Not necessarily. This is probably the biggest misunderstanding in the conversation. Lyophilized peptides are generally much more stable than peptides once they have been dissolved into a liquid. Removing most of the water during lyophilization reduces many of the chemical and physical processes that can cause degradation. However, “lyophilized” does not mean “immune to degradation.” Temperature, moisture, oxygen, light, formulation, sequence, residual water and packaging can all affect stability. Major laboratory suppliers commonly recommend cold storage for long-term preservation. For example, MilliporeSigma recommends storing lyophilized peptides at −20°C or colder, with −80°C suggested for longer-term storage when available. It also emphasizes minimizing moisture exposure and repeated temperature cycling. That is very different from saying: “Every peptide left outside a freezer for more than a few months is automatically destroyed.” There isn't a universal scientific cutoff like that.